Related Experiment Video
Updated: Apr 15, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
[Thiazolidine, thiazolidinediones, TZD]
Abstract:
In addition to a good efficacy to lower blood glucose without hypoglycemia, thiazolidinediones(TZDs) have been proved to have the effects to increase plasma adiponectin, and actually decrease the cardiovascular events in several randomized clinical trials, while some adverse effects have also been demonstrated such as increase of heart failure and born fracture, and fear of bladder cancer. Since TZDs could intervene the pathogenesis of adipocytes' hypertrophy and inflammation in adipose tissue, atherosclerotic lesions and liver by modulating PPARγ of adipocytes and macrophages, TZDs are still considered at the special position among other diabetic drugs, and require further evidence for their efficacy and safety.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Antihypertensive Drugs: Thiazide-Class Diuretics
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
